Veracyte, Inc. VCYT
10 trading plans running, 29 Form 144 notices for $18.0M
10-Q, 10-K and Form 144What VCYT's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.
Plans adopted or ended
Trading plans · XBRL, 10-Q and 10-K
From Aug 21, 2025 to Nov 26, 2027. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired. The ten newest plans are drawn; all are in the table.
| Insider | What | Date | Reported in | ||
|---|---|---|---|---|---|
| Phil Febbo Chief Scientific Officer and Chief Medical Officer |
Adopted 10b5-1 plan | Aug 12, 2026 | 10-Q Nov 5, 2026 | ||
What the company wrotePhil Febbo, Chief Scientific Officer and Chief Medical Officer, adopted a new trading plan on August 12, 2026 (with the first trade under the new plan scheduled for approximately November 30, 2026). The trading plan will be effective until November 26, 2027 to sell an aggregate of (i) 8,000 shares of our common stock, plus (ii) between 50% and 100% of the net shares resulting from the vesting of 87,844 restricted stock units during the plan period (net shares are net of tax withholding). | |||||
| Jens Holstein Director |
Adopted 10b5-1 plan | Jun 12, 2026 | 10-Q Jul 31, 2026 | ||
What the company wroteJens Holstein, Director, adopted a new trading plan on June 12, 2026 (with the first trade under the new plan scheduled for approximately September 11, 2026). The trading plan will be effective until June 7, 2027 to sell an aggregate of 20,000 shares of our common stock. | |||||
| John Leite Global Chief Commercial Officer |
Adopted 10b5-1 plan | Jun 9, 2026 | 10-Q Jul 31, 2026 | ||
What the company wroteJohn Leite, Global Chief Commercial Officer, adopted a new trading plan on June 9, 2026 (with the first trade under the new plan scheduled for approximately September 8, 2026). The trading plan will be effective until August 13, 2027 to sell 100% of the net shares resulting from the vesting of 44,270 restricted stock units during the plan period (net shares are net of tax withholding). | |||||
| Muna Bhanji Director |
Adopted 10b5-1 plan | Jun 2, 2026 | 10-Q Jul 31, 2026 | ||
What the company wroteMuna Bhanji, Director, adopted a new trading plan on June 2, 2026 (with the first trade under the new plan scheduled for approximately September 1, 2026). The trading plan will be effective until August 31, 2027 to sell an aggregate of 3,728 shares of our common stock. | |||||
| Karin Eastham Director |
Adopted 10b5-1 plan | May 28, 2026 | 10-Q Jul 31, 2026 | ||
What the company wroteKarin Eastham, Director, adopted a new trading plan on May 28, 2026 (with the first trade under the new plan scheduled for approximately August 27, 2026). The trading plan will be effective until May 7, 2027 to sell an aggregate of 23,841 shares of our common stock. | |||||
| Robert Epstein director |
Adopted 10b5-1 plan | Dec 5, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteRobert Epstein, director, adopted a new trading plan on December 5, 2025 (with the first trade under the new plan scheduled for approximately March 6, 2026). The trading plan will be effective until March 5, 2027 to sell an aggregate of 10,000 shares of our common stock. | |||||
| Marc Stapley Chief Executive Officer |
Adopted 10b5-1 plan | Nov 24, 2025 | 10-K Feb 26, 2026 | ||
What the company wroteMarc Stapley, Chief Executive Officer, adopted a new trading plan on November 24, 2025 (with the first trade under the new plan scheduled for approximately March 3, 2026). The trading plan will be effective until August 31, 2026 to sell an aggregate of (i) 138,051 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 69,476 restricted stock units during the plan period (net shares are net of tax withholding). | |||||
| Karin Eastham Director |
Adopted 10b5-1 plan | Sep 5, 2025 | 10-Q Nov 5, 2025 | ||
What the company wroteKarin Eastham, Director, adopted a new trading plan on September 5, 2025 (with the first trade under the new plan scheduled for approximately December 5, 2025). The trading plan will be effective until November 20, 2026 to sell an aggregate of 29,533 shares of our common stock. | |||||
| Annie McGuire General Counsel and Chief People Officer |
Adopted 10b5-1 plan | Aug 29, 2025 | 10-Q Nov 5, 2025 | ||
What the company wroteAnnie McGuire, General Counsel and Chief People Officer, adopted a new trading plan on August 29, 2025 (with the first trade under the new plan scheduled for approximately November 28, 2025). The trading plan will be effective until December 18, 2026 to sell an aggregate of (i) 7,671 shares of our common stock, plus (ii) specified percentages ranging between 33% and 100% of the net shares resulting from the vesting of 179,803 restricted stock units during the plan period (net shares are net of tax withholding). | |||||
| Jens Holstein Director |
Adopted 10b5-1 plan | Aug 21, 2025 | 10-Q Nov 5, 2025 | ||
What the company wroteJens Holstein, Director, adopted a new trading plan on August 21, 2025 (with the first trade under the new plan scheduled for approximately November 20, 2025). The trading plan will be effective until August 21, 2026 to sell an aggregate of 10,000 shares of our common stock. | |||||
| Rebecca Chambers Chief Financial Officer |
Adopted 10b5-1 plan | Aug 21, 2025 | 10-Q Nov 5, 2025 | ||
What the company wroteRebecca Chambers, Chief Financial Officer, adopted a new trading plan on August 21, 2025 (with the first trade under the new plan scheduled for approximately November 20, 2025). The trading plan will be effective until December 11, 2026 to sell an aggregate of (i) 10,000 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 82,188 restricted stock units during the plan period (net shares are net of tax withholding). | |||||
| •Phil Febbo Chief Scientific Officer and Chief Medical Officer |
Adopted 10b5-1 plan | Aug 21, 2025 | 10-Q Nov 5, 2025 | ||
What the company wrotePhil Febbo, Chief Scientific Officer and Chief Medical Officer, adopted a new trading plan on August 21, 2025 (with the first trade under the new plan scheduled for approximately February 28, 2026). The trading plan will be effective until November 27, 2026 to sell an aggregate of (i) 13,425 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 26,514 restricted stock units during the plan period (net shares are net of tax withholding). | |||||
| John Leite Global Chief Commercial Officer |
Adopted 10b5-1 plan | Jun 9, 2025 | 10-Q Aug 7, 2025 | ||
What the company wroteJohn Leite, Global Chief Commercial Officer, adopted a new trading plan on June 9, 2025 (with the first trade under the new plan scheduled for approximately September 8, 2025). The trading plan will be effective until September 18, 2026 to sell an aggregate of (i) 9,077 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 42,137 additional common stock during the plan period (net shares are net of tax withholding). | |||||
| Robert Epstein director |
Adopted 10b5-1 plan | Mar 6, 2025 | 10-Q May 8, 2025 | ||
What the company wroteRobert Epstein, director, adopted a new trading plan on March 6, 2025 (with the first trade under the new plan scheduled for approximately June 5, 2025). The trading plan will be effective until May 29, 2026 to sell an aggregate of 21,473 shares of our common stock. | |||||
| Evan Jones director |
Adopted 10b5-1 plan | Dec 9, 2024 | 10-K Feb 28, 2025 | ||
What the company wroteEvan Jones, director, adopted a new trading plan on December 9, 2024 (with the first trade under the new plan scheduled for March 12, 2025). The trading plan will be effective until March 11, 2026 to sell an aggregate of 48,196 shares of our common stock. | |||||
| John Leite Chief Commercial Officer, CLIA |
Adopted 10b5-1 plan | Dec 6, 2024 | 10-K Feb 28, 2025 | ||
What the company wroteJohn Leite, Chief Commercial Officer, CLIA, adopted a new trading plan on December 6, 2024 (with the first trade under the new plan scheduled for March 7, 2025). The trading plan will be effective until December 31, 2025 to sell 100% of the net shares resulting from the vesting of 20,770 shares of common stock during the plan period (net shares are net of tax withholding). | |||||
| Muna Bhanji director |
Adopted 10b5-1 plan | Nov 11, 2024 | 10-K Feb 28, 2025 | ||
What the company wroteMuna Bhanji, director, adopted a new trading plan on November 11, 2024 (with the first trade under the new plan scheduled for approximately June 13, 2025). The trading plan will be effective until February 27, 2026 to sell an aggregate of 4,589 shares of our common stock. | |||||
| Marc Stapley Chief Executive Officer |
Adopted 10b5-1 plan | Sep 13, 2024 | 10-Q Nov 7, 2024 | ||
What the company wroteMarc Stapley, Chief Executive Officer, adopted a new trading plan on September 13, 2024 (with the first trade under the new plan scheduled for December 13, 2024). The trading plan will be effective until December 11, 2025 to sell 100% of the net shares resulting from the vesting of 151,087 common stock during the plan period (net shares are net of tax withholding). | |||||
| Annie McGuire General Counsel and Chief People Officer |
Adopted 10b5-1 plan | Sep 4, 2024 | 10-Q Nov 7, 2024 | ||
What the company wroteAnnie McGuire, General Counsel and Chief People Officer, adopted a new trading plan on September 4, 2024 (with the first trade under the new plan scheduled for December 4, 2024). The trading plan will be effective until December 15, 2025 to sell an aggregate of (i) 14,970 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 31,175 additional common stock during the plan period (net shares are net of tax withholding). | |||||
| Phillip Febbo Chief Scientific Officer and Chief Medical Officer |
Adopted 10b5-1 plan | Sep 4, 2024 | 10-Q Nov 7, 2024 | ||
What the company wrotePhillip Febbo, Chief Scientific Officer and Chief Medical Officer, adopted a new trading plan on September 4, 2024 (with the first trade under the new plan scheduled for December 4, 2024). The trading plan will be effective until November 21, 2025 to sell an aggregate of (i) 100% of the net shares resulting from the vesting of 38,230 common stock during the plan period, plus (ii) 10% of the net shares resulting from the vesting of 25,528 additional common stock during the plan period (net shares are net of tax withholding). | |||||
| Karin Eastham director |
Adopted 10b5-1 plan | Aug 20, 2024 | 10-Q Nov 7, 2024 | ||
What the company wroteKarin Eastham, director, adopted a new trading plan on August 20, 2024 (with the first trade under the new plan scheduled for November 19, 2024). The trading plan will be effective until November 14, 2025 to sell an aggregate of 38,955 shares of our common stock. | |||||
| Rebecca Chambers Chief Financial Officer |
Adopted 10b5-1 plan | Aug 13, 2024 | 10-Q Nov 7, 2024 | ||
What the company wroteRebecca Chambers, Chief Financial Officer, adopted a new trading plan on August 13, 2024 (with the first trade under the new plan scheduled for November 12, 2024). The trading plan will be effective until November 21, 2025 to sell an aggregate of 29,802 shares of our common stock. | |||||
| Robert Epstein director |
Adopted 10b5-1 plan | Aug 9, 2024 | 10-Q Nov 7, 2024 | ||
What the company wroteRobert Epstein, director, adopted a new trading plan on August 9, 2024 (with the first trade under the new plan scheduled for approximately November 11, 2024). The trading plan will be effective until January 11, 2025 to sell an aggregate of 15,000 shares of our common stock. | |||||
| Jens Holstein director |
Adopted 10b5-1 plan | Mar 11, 2024 | 10-Q May 8, 2024 | ||
What the company wroteJens Holstein, director, adopted a new trading plan on March 11, 2024 (with the first trade under the new plan scheduled for June 10, 2024). The trading plan will be effective until December 31, 2024 to sell an aggregate of 10,000 shares of our common stock. | |||||
| Karin Eastham director |
Adopted 10b5-1 plan | Mar 8, 2024 | 10-Q May 8, 2024 | ||
What the company wroteKarin Eastham, director, adopted a new trading plan on March 8, 2024 (with the first trade under the new plan scheduled for June 7, 2024). The trading plan will be effective until March 7, 2025 to sell an aggregate of 13,870 shares of our common stock. | |||||
| John Leite Chief Commercial Officer |
Adopted 10b5-1 plan | Mar 1, 2024 | 10-Q May 8, 2024 | ||
What the company wroteJohn Leite, Chief Commercial Officer, CLIA, adopted a new trading plan on March 1, 2024 (with the first trade under the new plan scheduled for June 4, 2024). The trading plan will be effective until February 27, 2025 to sell an aggregate of (i) 5,252 shares of our common stock, plus (ii) 100% of the net shares resulting from the vesting of 5,183 additional common stock during the plan period (net shares are net of tax withholding). | |||||
| Evan Jones director |
Adopted 10b5-1 plan | Feb 28, 2024 | 10-Q May 8, 2024 | ||
What the company wrotejVen Capital LLC (Evan Jones, director, is the managing member of jVen Capital LLC) adopted a new trading plan on February 28, 2024 (with the first trade under the new plan scheduled for June 10, 2024). The trading plan will be effective until December 31, 2025 to sell an aggregate of 35,173 shares of our common stock. | |||||
| Evan Jones director |
Adopted 10b5-1 plan | Feb 28, 2024 | 10-Q May 8, 2024 | ||
What the company wroteEvan Jones, director, adopted a new trading plan on February 28, 2024 (with the first trade under the new plan scheduled for June 10, 2024). The trading plan will be effective until December 31, 2025 to sell an aggregate of 24,731 shares of our common stock. | |||||
| Muna Bhanji director |
Adopted 10b5-1 plan | Feb 27, 2024 | 10-Q May 8, 2024 | ||
What the company wroteMuna Bhanji, director, adopted a new trading plan on February 27, 2024 (with the first trade under the new plan scheduled for approximately May 10, 2024). The trading plan will be effective until February 28, 2025 to sell an aggregate of 5,409 shares of our common stock. | |||||
Show the other 21 plans
From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 5, 2023.
Notices of planned sales
Form 144 · Form 144 XML, SEC
What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).
| Filed | Seller | Shares | Value |
|---|---|---|---|
| Oct 27, 2026 | KARIN EASTHAM Director |
14,850 | $716K |
| Oct 27, 2026 | JENS HOLSTEIN Director |
7,500 | $375K |
| Sep 24, 2026 | JENS HOLSTEIN Director |
7,500 | $352K |
| Sep 21, 2026 | JOHN LEITE Officer |
4,015 | $160K |
| Sep 14, 2026 | JENS HOLSTEIN Director |
5,000 | $205K |
| Sep 4, 2026 | ANN MCGUIRE Officer |
3,254 | $145K |
| Sep 4, 2026 | REBECCA CHAMBERS Officer |
3,652 | $163K |
| Sep 4, 2026 | PHILLIP FEBBO Officer |
13,110 | $586K |
| Sep 1, 2026 | MUNA BHANJI Director |
3,728 | $161K |
| Jun 18, 2026 | KARIN EASTHAM Director |
3,729 | $191K |
| Jun 4, 2026 | ANN MCGUIRE Officer |
3,176 | $155K |
| Jun 4, 2026 | John Leite Officer |
13,975 | $680K |
| Jun 4, 2026 | MARC STAPLEY Director, Officer |
138,051 | $6.7M |
| Jun 4, 2026 | REBECCA CHAMBERS Officer |
3,561 | $173K |
| May 20, 2026 | ROBERT EPSTEIN Director |
10,000 | $417K |
| May 6, 2026 | ANN MCGUIRE Officer |
10,204 | $336K |
| Mar 4, 2026 | ANN MCGUIRE Officer |
6,658 | $234K |
| Mar 4, 2026 | John Leite Officer |
5,260 | $185K |
| Mar 4, 2026 | REBECCA CHAMBERS Officer |
18,341 | $643K |
| Mar 4, 2026 | MARC STAPLEY Director, Officer |
45,523 | $1.6M |
| Mar 2, 2026 | PHILLIP FEBBO Officer |
13,425 | $491K |
| Dec 16, 2025 | ANN MCGUIRE Officer |
10,739 | $467K |
| Dec 5, 2025 | KARIN EASTHAM Director |
20,000 | $948K |
| Dec 4, 2025 | ANN MCGUIRE Officer |
1,422 | $68K |
| Dec 4, 2025 | REBECCA CHAMBERS Officer |
13,278 | $634K |
| Dec 4, 2025 | MARC STAPLEY Director, Officer |
7,668 | $366K |
| Nov 25, 2025 | Evan Jones Director |
5,000 | $247K |
| Nov 25, 2025 | John Leite Officer |
4,086 | $191K |
| Nov 20, 2025 | JENS HOLSTEIN Director |
10,000 | $424K |
Show the other 21 notices
From the Form 144 XML filed with the SEC, since Nov 20, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.
Sources
Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.
Also
Insider trades: the Form 4s for the sales these plans led to.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/VCYT/export.csv") into a cell.